Core Insights - Grace Therapeutics, Inc. is a late-stage biopharma company focused on developing GTx-104, a novel injectable formulation of nimodipine for IV infusion targeting aneurysmal subarachnoid hemorrhage (aSAH) patients [1][5][6] - The company will be represented by CEO Prashant Kohli at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York [1][2] Company Overview - Grace Therapeutics specializes in drug candidates for rare and orphan diseases, utilizing novel drug delivery technologies to enhance drug performance, including faster onset of action and reduced side effects [6] - The lead clinical asset, GTx-104, has received Orphan Drug Designation from the FDA, granting seven years of marketing exclusivity post-launch in the U.S. and additional intellectual property protection with over 40 patents [6] Product Details - GTx-104 is designed for IV infusion in aSAH patients, addressing significant unmet medical needs and potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients [5] - The product has been administered to over 200 patients and healthy volunteers, demonstrating good tolerance and lower pharmacokinetic variability compared to oral nimodipine [5] Industry Context - Aneurysmal subarachnoid hemorrhage (aSAH) is a rare type of stroke, accounting for about 5% of all strokes, with an estimated 42,500 hospital-treated patients in the U.S. [4]